Period Pain Relief That Actually Works: The Guideline Says Stop Normalizing It

Why does period pain happen

Primary dysmenorrhea is painful menstrual cramping without pelvic disease behind it. People with dysmenorrhea have elevated prostaglandin levels, and prostaglandins drive the uterine contractions that hurt. That is exactly why NSAIDs are first-line: they block prostaglandin production.

The scale is larger than the casual framing suggests. Up to 90 percent of people of reproductive age are affected, and up to 15 percent have symptoms severe enough to limit daily activity or force absences. Distinct from all this is secondary dysmenorrhea, where a condition such as endometriosis or fibroids sits underneath, a distinction that returns in the "when to see a doctor" section.

What does the evidence support

The reference document is SOGC Guideline No. 345 (2025), and its opening line is the reason this article exists. Dysmenorrhea is common among adolescents and women, frequently normalized and undertreated; treatment interventions do not depend on confirming a specific diagnosis and should not be delayed. The claim that period pain is just something you live with is contradicted in the guideline's own text.

First-line treatment runs on two tracks. NSAID efficacy was confirmed in a meta-analysis of 35 randomized controlled trials. Yet in a review spanning 51 clinical trials, 18 percent of women reported little or no relief from NSAIDs, and the failure rate across the literature runs 15 to 25 percent. There is little evidence that any single NSAID beats the others on relief or safety, and none that COX-2 selective drugs work better. Which drug matters less than watching whether it works.

Where NSAIDs fail, cannot be used, or contraception is also wanted, hormonal contraception is an established option. Combined oral contraceptives are the most studied, with the patch, ring, injection and the levonorgestrel IUD also recognized. Regimen appears to matter too: continuous low-dose estrogen-progestin dosing reduced the number of days with menstrual pain compared with cyclic dosing that pauses every 28 days. Knowing such options exist is this article's job; choosing among them belongs in a consulting room.

And then there is heat. A 2025 systematic review and meta-analysis reported that topical heat may deliver pain relief comparable to NSAIDs. The oldest advice in this topic, warmth on the abdomen, turns out to be the folk remedy with receipts. The size of that evidence base, and the adjuncts the SOGC guideline lists alongside heat, are laid out below in "What you can try tonight."

How do three countries route you to treatment

The medicine is internationally uniform. What splits by country is the route to it, above all the route to hormonal contraception.

Table: oral contraceptive access and period-pain treatment systems compared by country.

United States: the door that opened in 2023

US

The United States approved its first over-the-counter daily birth control pill on July 13, 2023. The FDA cleared Opill, a progestin-only norgestrel tablet, as the first daily oral contraceptive in American history available without a prescription. The decision followed a public advisory committee meeting, and the American College of Obstetricians and Gynecologists called it a critically important advance for reproductive health access. Sales began in March 2024 online and at major retailers. The FDA was explicit that all other formulations and doses of oral contraceptives remain prescription-only, and as an OTC product Opill is not covered by insurance.

The point of this section is that the order of access runs opposite to the stereotype. The country assumed to have the widest medical access got its first OTC pill in 2023, while pharmacies in South Korea had been selling daily pills without a prescription for decades.

South Korea: decades over the counter, with a footnote

KR

In Korea, daily oral contraceptives are classified as over-the-counter drugs, sold at any pharmacy without a prescription, and they have been for more than twenty years. Emergency contraception runs the other way: prescription-only. Internationally, the usual combination is the reverse, daily pills behind a prescription and the morning-after pill in front of it. Korea flipped both.

The classification has a history. In June 2012 the regulator announced a plan to reclassify both drugs toward the international norm, shelved it amid public controversy, ran a three-year study of 6,500 people, and in May 2016 decided to keep the existing classification. The remarkable part is the stated reasoning: the agency said that scientifically, daily pills should be prescription and emergency pills should be OTC, but that it was deferring to established usage patterns. A regulator conceding on the record that the science points the other way, and the classification standing for a decade since. Concern about misuse was cited for keeping emergency contraception behind a prescription.

For period pain, the catch is that open access and actual treatment are different things. Buying the pill is easy; saying "it hurts" to a doctor is a separate, harder step. Whether you fall in the 15 to 25 percent whom NSAIDs fail, or whether something secondary like endometriosis is underneath, is not something a pharmacy counter can tell you. Korea's insurance status and clinical statistics for dysmenorrhea care were not verified for this article, and we would rather note that than guess.

Japan: the system that asks why you take it

JP

In Japan the low-dose pill splits in two by purpose. The oral contraceptive (OC) is prescribed for contraception at the patient's own expense. But a formulation with the same types and amounts of hormones is separately approved for treating menstrual pain and endometriosis-related pain, and that version, called LEP (low-dose estrogen-progestin), is covered by insurance. The standard reference is the OC and LEP guideline jointly edited by the Japan Society of Obstetrics and Gynecology and the Japan Society for Menopause and Women's Health.

The sequence is inverted too. Health ministry records show that the oral contraceptive submitted for approval in Japan was derived from hormone preparations already used to treat menstrual disorders, with the hormone content reduced. The treatment came first; the contraceptive followed.

The same compound changes name and price depending on why you take it. For contraception, you pay; for period pain, insurance pays. The system asks the question Korea's pharmacy counter never asks, and in exchange, everyone treating period pain with the pill in Japan passes through a consulting room first.

Lay the three side by side. One country left the door open by custom, one asks your reason and bills accordingly, and one opened a single product's worth of door in 2023. None of the designs is free. The open door costs unexamined self-treatment, the questioning system costs a threshold, and the late door cost decades of waiting.

In migraine prevention the gate sits inside the reimbursement rule rather than the pharmacy counter: the response rates were identical across two countries, and one of them still requires three failed medications at maximum doses over six months before it pays.

What you can try tonight

The systems differ by country. This part does not. In order:

Heat comes first. The 2025 systematic review and meta-analysis searched seven databases and pooled 57 randomized trials with 5,359 participants. Its finding was that heat therapy may produce pain relief comparable to NSAIDs while possibly carrying a better safety profile. The certainty of that evidence was rated low, and that caveat travels with the finding. Even so, few things you can reach for tonight have this many trials behind them.

The adjuncts the SOGC lists. The same guideline names high-frequency transcutaneous electrical nerve stimulation (TENS), topical heat in the form of pads and patches, acupoint stimulation, and ginger supplementation as adjunctive treatments. Two qualifiers come attached: the strength and certainty of the evidence vary (conditional, low certainty), and the guideline frames these as options to consider particularly for women who cannot use or choose not to use conventional treatment. Read the list without those qualifiers and you have misread it.

Watching whether a drug works beats choosing between drugs. There is little evidence that any single NSAID outperforms the others on relief or safety, and none that COX-2 selective inhibitors work better. Time spent deciding which one matters less than paying attention to whether the one you took is working.

If it does not work, stop enduring it. Between 15 and 25 percent get little or no relief from NSAIDs. If that is you, the next step the guideline points to is a conversation about hormonal treatment and an evaluation for secondary causes. And the SOGC sentence bears repeating here: treatment interventions do not depend on confirming a specific diagnosis and should not be delayed. Pain treatment can start while the cause is still being worked out.

Which preparation and which regimen suit you is not something this article can settle. These are drugs that require risk assessment and a prescription, and that judgment belongs in a consulting room.

When to see a doctor

• The painkillers are not working. NSAIDs fail 15 to 25 percent of the people who try them, and that failure is itself the indication to discuss the next step.
• There is no reason to wait. The guideline states that treatment does not depend on confirming a diagnosis and should not be delayed.
• Secondary causes exist. Endometriosis, fibroids, adenomyosis and cervical stenosis are the common ones, assessed with history, pelvic examination and usually transvaginal ultrasound.
• If you take a combined hormonal product, know the thrombosis warning signs: sudden abdominal pain, chest pain or shortness of breath, severe headache, vision or speech changes, severe pain or swelling in one leg. Stop the drug and seek emergency care immediately, and tell the clinicians what you are taking.
• Surgery is considered only when pain persists despite optimized medical treatment or a secondary cause is strongly suspected.

Frequently asked questions

Frequently asked

Is severe period pain just normal?

No, and the strongest statement of that is in the guideline itself: dysmenorrhea is frequently normalized and undertreated, and treatment should not be delayed. Up to 15 percent of those affected have symptoms severe enough to shut down daily activity. Common is not the same as fine.

How often do painkillers simply fail?

In 15 to 25 percent of cases, by the pooled literature; one large review put it at 18 percent reporting little or no relief. If that is you, the evidence-backed next step is a conversation about hormonal treatment and an evaluation for secondary causes, not a bigger dose of endurance.

Why does Japan bill the same pill differently?

Because the system classifies by purpose. The contraceptive version (OC) is out of pocket; the pharmacologically equivalent version approved for menstrual-pain treatment (LEP) is insured. The treatment indication actually predates the contraceptive one in Japan's approval history.

When is period pain a sign of something else?

When it escalates over time, persists outside menstruation, or resists first-line treatment. The common secondary causes are endometriosis, fibroids, adenomyosis and cervical stenosis, and they are evaluated with history, a pelvic exam and ultrasound. Pain that outgrows its old pattern has earned an appointment.